Medically reviewed by FormBlends physician team. Last updated March 2026.
Key Takeaway
Complete guide to VIP peptide (vasoactive intestinal peptide). Learn about CIRS treatment protocols, nasal spray dosing, anti-inflammatory benefits, and how VIP therapy works.
Quick Answer: VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide with potent anti-inflammatory, immunoregulatory, and neuroprotective properties. It's best known as the final step in Dr. Ritchie Shoemaker's CIRS treatment protocol, where VIP nasal spray at 50 mcg four times daily normalizes inflammatory biomarkers in over 90% of protocol-compliant patients. VIP also holds FDA Orphan Drug designation for pulmonary arterial hypertension and matters in circadian rhythm regulation.
What Is VIP Peptide?
VIP stands for vasoactive intestinal peptide. It's an endogenous neuropeptide, meaning your body naturally produces it. First isolated from porcine small intestine by Said and Mutt in 1970, VIP has since been recognized as one of the most functionally diverse signaling molecules in human physiology.
The peptide consists of 28 amino acids with the sequence His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2, and has a molecular weight of approximately 3,326 Daltons. Despite being discovered in the gut, VIP is produced throughout the body, including the brain, lungs, pancreas, and immune cells.
VIP isn't a synthetic drug. It's a bioidentical copy of a peptide your body already makes. When VIP levels are depleted, as happens in chronic inflammatory conditions like CIRS from mold exposure, replacing it with exogenous VIP restores the regulatory functions your immune system depends on.
How VIP Works: Receptor Pharmacology and Signaling
VIP produces its effects by binding to two G-protein-coupled receptors: VPAC1 and VPAC2. Understanding which receptor is active in which tissue explains why VIP has such broad therapeutic applications.
View data table
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
| Receptor | Primary Locations | Key Functions |
|---|---|---|
| VPAC1 | Immune cells (T-cells, macrophages, dendritic cells), epithelial cells, neurons | Anti-inflammatory signaling, T-cell polarization, mucosal immunity |
| VPAC2 | Smooth muscle, suprachiasmatic nucleus (brain clock), pancreatic beta cells | Smooth muscle relaxation, circadian rhythm synchronization, insulin secretion |
Both receptors couple to Gs proteins, which activate adenylyl cyclase and raise intracellular cAMP levels. This triggers the cAMP/PKA/CREB signaling cascade, which is responsible for most of VIP's downstream effects. In practical terms, when VIP binds its receptor, it turns on anti-inflammatory gene transcription, relaxes smooth muscle tissue, and activates neuroprotective pathways.
What makes VIP unique among anti-inflammatory compounds is that it doesn't cause immunosuppression. Instead of shutting down the immune system, VIP redirects it. It shifts immune responses from destructive inflammatory patterns toward regulated, tolerogenic patterns. This distinction matters enormously for patients with autoimmune conditions or chronic inflammatory syndromes.
VIP Peptide Benefits
The benefits of VIP peptide therapy span multiple organ systems. This is because VPAC1 and VPAC2 receptors are distributed throughout the body, and VIP's signaling cascade affects fundamental inflammatory and regulatory pathways.
From the FormBlends catalog
VIP (Vasoactive Intestinal Peptide)
Neuropeptide that regulates inflammation, circadian rhythm, and mucosal immunity · From $59/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about VIP (Vasoactive Intestinal Peptide) →Anti-Inflammatory Effects
VIP suppresses NF-kB-dependent transcription in macrophages, which reduces production of the inflammatory cytokines TNF-alpha, IL-6, IL-12, and nitric oxide. It simultaneously promotes generation of CD4+CD25+FoxP3+ regulatory T-cells (Tregs) that actively suppress autoimmune and inflammatory responses. These mechanisms have been demonstrated in published models of rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and septic shock.
Immune Regulation
VIP shifts T-cell differentiation from pro-inflammatory Th1/Th17 phenotypes toward regulatory Th2/Treg phenotypes. It does this by modulating dendritic cell maturation, which are the immune cells responsible for "training" T-cells. This isn't immunosuppression. It's immune recalibration, restoring the balance between inflammatory attack and regulatory tolerance.
Neuroprotection
In the brain, VIP protects neurons against glutamate excitotoxicity and reduces microglial activation (the brain's inflammatory response). This neuroprotective function is relevant to patients with CIRS-related cognitive dysfunction, neuroinflammatory conditions, and age-related cognitive decline.
Respiratory Function
VIP acts as both a bronchodilator and pulmonary vasodilator. It relaxes smooth muscle in the airways and pulmonary blood vessels, improving oxygen exchange and reducing pulmonary arterial pressure. This is why VIP has received FDA Orphan Drug designation for pulmonary arterial hypertension.
Circadian Rhythm Regulation
VIP neurons in the suprachiasmatic nucleus (SCN) serve as the dominant synchronizing signal for the body's master circadian clock. Without adequate VIP signaling, circadian rhythms fragment, disrupting sleep-wake cycles, hormonal rhythms, and metabolic timing.
| System | Mechanism | Clinical Relevance |
|---|---|---|
| Immune | Th1/Th17 to Th2/Treg shift via dendritic cell modulation | CIRS, autoimmune conditions, chronic inflammation |
| Inflammatory | NF-kB suppression, TNF-alpha/IL-6/IL-12 reduction | Biotoxin illness, systemic inflammatory states |
| Neurological | Anti-excitotoxicity, reduced microglial activation | Brain fog, cognitive dysfunction, neuroinflammation |
| Pulmonary | Bronchodilation, pulmonary vasodilation | PAH (Orphan Drug designation), shortness of breath |
| Circadian | SCN neuron synchronization | Sleep disruption, shift work, jet lag |
| Gastrointestinal | Mucosal immunity, smooth muscle regulation | Gut inflammation, IBD |
VIP and CIRS Treatment: The Shoemaker Protocol
The most established clinical use of VIP peptide is as the final step in Dr. Ritchie Shoemaker's treatment protocol for Chronic Inflammatory Response Syndrome (CIRS). CIRS is a multisystem illness triggered by biotoxin exposure, most commonly from water-damaged buildings containing mold species like Stachybotrys chartarum.
CIRS depletes endogenous VIP production, which removes one of the body's primary anti-inflammatory regulators. Without adequate VIP, the inflammatory cascade triggered by biotoxin exposure continues unchecked, producing symptoms across multiple organ systems: fatigue, cognitive dysfunction, shortness of breath, joint pain, light sensitivity, and temperature dysregulation.
Why VIP Is the Final Step
VIP nasal spray isn't introduced until patients have completed all prior steps of the Shoemaker protocol. These preparatory steps include removing the patient from the biotoxin source, binding toxins with cholestyramine or welchol, correcting MARCoNS (nasal staph colonization), addressing abnormal MMP-9 and VEGF levels, and normalizing other inflammatory markers. Skipping these steps and going directly to VIP won't produce lasting results.
CIRS Biomarker Normalization
Clinical data from CIRS treatment cohorts shows that VIP nasal spray normalizes the following biomarkers in over 90% of protocol-compliant patients:
| Biomarker | Pre-VIP (Typical CIRS) | Post-VIP (After Treatment) | Normal Range |
|---|---|---|---|
| TGF-beta1 | 5,000-15,000+ pg/mL | <2,380 pg/mL | <2,380 pg/mL |
| MMP-9 | 500-1,500+ ng/mL | <332 ng/mL | 85-332 ng/mL |
| C4a | 5,000-20,000+ ng/mL | <2,830 ng/mL | 0-2,830 ng/mL |
| VEGF | Often <31 pg/mL | 31-86 pg/mL | 31-86 pg/mL |
VIP also restores the gray matter nuclear atrophy visible on NeuroQuant MRI in CIRS patients, which is a structural brain change that correlates with cognitive symptoms.
If you suspect you have CIRS or are dealing with biotoxin illness, VIP therapy is available through FormBlends under physician supervision. Our providers are experienced in the full Shoemaker protocol and can guide you through each step.
VIP Dosage Protocols
VIP dosage depends on the route of administration and the condition being treated. The most common clinical route is intranasal (nasal spray), which delivers VIP directly to brain tissue via the olfactory pathway and to pulmonary tissue via mucosal absorption.
Why Nasal Spray?
VIP has a plasma half-life of only 1 to 2 minutes when injected systemically. It's rapidly broken down by two enzymes: dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP). Intranasal delivery bypasses this rapid systemic degradation, allowing VIP to reach its target tissues at therapeutic concentrations.
| Route | Indication | Dose | Frequency | Duration |
|---|---|---|---|---|
| Intranasal spray | CIRS (Shoemaker protocol) | 50 mcg per spray | 4 times daily | 30-90 days (biomarker-guided) |
| Intranasal spray | Pulmonary support | 50-100 mcg per spray | 2-4 times daily | Physician-directed |
| Subcutaneous injection | Research protocols | Physician-determined | Varies by protocol | Physician-directed |
Dose Timing Considerations
Given VIP's role in circadian rhythm regulation through the suprachiasmatic nucleus, some practitioners recommend spacing doses evenly throughout the waking day. A common schedule is upon waking, midday, late afternoon, and before bed. Consistency in timing helps maintain steady VIP receptor activation.
Monitoring During VIP Therapy
Your physician should monitor CIRS biomarkers (TGF-beta1, MMP-9, C4a, VEGF) at baseline and at regular intervals during VIP therapy. Treatment duration is guided by biomarker normalization rather than a fixed timeline. Some patients achieve normalization within 30 days, while others require the full 90-day course.
VIP and Circadian Rhythm Regulation
Beyond its anti-inflammatory role, VIP serves as the primary synchronizing signal in the brain's master clock. VIP-expressing neurons in the suprachiasmatic nucleus (SCN) coordinate the firing patterns of neighboring clock neurons, keeping circadian rhythms coherent across the body.
Research using VIP knockout mice demonstrates severe consequences of VIP depletion on circadian function:
- Fragmented sleep-wake cycles with disrupted REM and non-REM architecture
- Irregular feeding rhythms and altered metabolic timing
- Disrupted cortisol, melatonin, and growth hormone release patterns
- Impaired temperature regulation throughout the day-night cycle
For patients with CIRS, who often report severe sleep disruption as one of their most debilitating symptoms, VIP's circadian restoration may explain why so many patients describe improved sleep quality early in VIP therapy, often before full biomarker normalization occurs.
This circadian role also makes VIP relevant to shift workers, frequent travelers, and older adults experiencing age-related circadian deterioration, though clinical applications in these populations are still being investigated.
VIP for Pulmonary Health
VIP has received FDA Orphan Drug designation for pulmonary arterial hypertension (PAH), based on its potent bronchodilatory and vasodilatory effects in the pulmonary vasculature. This is one of the few official regulatory recognitions of VIP's therapeutic potential.
In the lungs, VIP relaxes pulmonary arterial smooth muscle, reduces pulmonary vascular resistance, and improves gas exchange. CIRS patients frequently present with shortness of breath and reduced exercise tolerance. These respiratory symptoms correlate with pulmonary inflammation and vasoconstriction that VIP directly addresses.
The intranasal route of administration is particularly advantageous for pulmonary applications because a portion of the nasal spray dose is absorbed through the respiratory mucosa, delivering VIP directly to the pulmonary tissue where it's needed.
VIP and Gut Health
VIP was originally discovered in the gut, and it maintains critical functions throughout the gastrointestinal tract. It regulates smooth muscle contraction, mucosal blood flow, epithelial cell secretion, and local immune responses in the intestinal lining.
In the context of inflammatory bowel conditions, VIP's anti-inflammatory signaling through mucosal VPAC1 receptors helps reduce the Th1/Th17-driven inflammation that damages intestinal tissue. This mechanism is complementary to other gut-healing peptides like BPC-157 (which drives tissue repair) and KPV (which suppresses localized NF-kB activation). For a detailed comparison of these three peptides for gut inflammation, see our BPC-157 vs KPV vs VIP comparison guide.
VIP vs Other Anti-Inflammatory Peptides
Patients often ask how VIP compares to other anti-inflammatory peptides available through FormBlends. The key distinction is that each peptide works through a different mechanism, which means they're better suited to different conditions rather than being interchangeable alternatives.
| Feature | VIP | BPC-157 | KPV | Thymosin Alpha-1 |
|---|---|---|---|---|
| Primary Mechanism | Immune repolarization (Th1/Th17 to Th2/Treg) | Tissue repair via growth factor upregulation | NF-kB pathway suppression | Dendritic cell activation, NK cell enhancement |
| Best For | CIRS, systemic autoimmunity, circadian disruption | Tendon/muscle/gut tissue damage | Localized inflammation, skin conditions, gut inflammation | Immune deficiency, chronic infections |
| Route | Intranasal (primary), subcutaneous | Subcutaneous injection, oral (BPC Arginate) | Subcutaneous injection, topical | Subcutaneous injection |
| Onset | 2-4 weeks (biomarkers), 4-8 weeks (symptoms) | 1-2 weeks | 1-3 weeks | 2-4 weeks |
| FDA Status | Orphan Drug designation (PAH) | Not FDA-approved | Not FDA-approved | FDA-approved internationally |
For a deeper look at how VIP compares specifically to KPV for inflammation and CIRS, see our VIP vs KPV comparison article.
VIP Stacking Protocols
Because VIP works through distinct receptor pathways (VPAC1/VPAC2), it can be combined with other peptides without receptor competition or interference. Common stacking approaches include:
VIP + BPC-157 (CIRS with Tissue Damage)
For CIRS patients who also have gut damage, joint injury, or chronic tendon problems, combining VIP nasal spray with BPC-157 injections addresses both the systemic immune dysregulation (VIP) and localized tissue repair (BPC-157). These peptides work through completely different pathways and don't interfere with each other.
VIP + KPV (Multi-Layer Anti-Inflammatory)
VIP modulates the adaptive immune system at the T-cell level, while KPV directly suppresses NF-kB inflammatory signaling. Together, they address inflammation from two different angles, which can be particularly valuable for patients with both systemic and localized inflammatory conditions.
VIP + Thymosin Alpha-1 (Immune Reconstitution)
For patients with CIRS who also show signs of immune deficiency (frequent infections, low NK cell function), combining VIP with Thymosin Alpha-1 can restore both immune regulation and immune competence. VIP recalibrates the inflammatory response while Thymosin Alpha-1 strengthens the body's ability to fight infections.
All stacking protocols should be designed and monitored by your physician. Schedule a consultation with FormBlends to discuss which combination is appropriate for your situation.
Storage and Reconstitution
Proper handling of VIP is critical because the peptide is sensitive to degradation. VIP contains a methionine residue at position 17 that's vulnerable to oxidation, which can reduce potency.
Storage Guidelines
| Form | Temperature | Stability | Notes |
|---|---|---|---|
| Lyophilized powder (unopened) | -20C (freezer) | 12+ months | Protect from light and moisture |
| Reconstituted nasal spray | 2-8C (refrigerator) | 30 days | Don't freeze. minimize air exposure |
| Reconstituted injection | 2-8C (refrigerator) | 14-28 days | Use bacteriostatic water. protect from light |
Reconstitution for Nasal Spray
VIP nasal spray is typically compounded by a licensed pharmacy. If you receive lyophilized VIP for reconstitution calculator, use bacteriostatic water for injection. The concentration will be determined by your prescribing physician based on the spray device calibration (each spray delivers a fixed volume, so the concentration determines the mcg per spray).
Don't freeze reconstituted nasal spray solutions. Freeze-thaw cycles can degrade the peptide and reduce its effectiveness. Keep the spray bottle refrigerated between uses and discard after 30 days.
Safety Profile and Side Effects
VIP has an established safety record from both clinical trials and extensive use in CIRS treatment protocols. At the standard intranasal dose of 50 mcg four times daily, VIP is well-tolerated.
Common Side Effects (Nasal Spray)
- Mild nasal irritation or tingling at the application site
- Transient nasal congestion (usually resolves within minutes)
- Occasional mild headache during the first few days
Possible Effects at Higher Systemic Doses
- Transient hypotension (consistent with VIP's vasodilatory activity)
- Facial flushing
- Watery diarrhea (consistent with VIP's enteric secretomotor function)
Important Safety Distinction
VIP doesn't suppress the immune system. This is a critical distinction from corticosteroids, TNF-alpha inhibitors, and other anti-inflammatory drugs that achieve their effects by broadly suppressing immune function. VIP redirects immune responses from destructive inflammatory patterns toward regulated, tolerogenic patterns. Your immune system remains fully functional, just properly calibrated.
Who Should Not Use VIP
- Patients who haven't completed the preliminary steps of the Shoemaker protocol (for CIRS treatment)
- Patients with active MARCoNS colonization (nasal staph must be treated first)
- Pregnant or nursing women (insufficient safety data)
- Patients with active malignancy (theoretical concern about immune modulation)
Frequently Asked Questions
What is VIP peptide used for?
VIP (vasoactive intestinal peptide) is primarily used in CIRS (Chronic Inflammatory Response Syndrome) treatment protocols as the final step in the Shoemaker protocol. It's also researched for autoimmune conditions, inflammatory bowel disease, pulmonary hypertension, and circadian rhythm disorders. VIP has FDA Orphan Drug designation for pulmonary arterial hypertension.
What is the standard VIP nasal spray dosage for CIRS?
The standard CIRS protocol uses VIP nasal spray at 50 mcg administered four times daily. Treatment duration typically ranges from 30 to 90 days depending on biomarker response. Patients must complete all prior steps of the Shoemaker protocol before starting VIP therapy.
Does VIP peptide have FDA approval?
VIP has received FDA Orphan Drug designation for the treatment of pulmonary arterial hypertension. It isn't FDA-approved for CIRS or other conditions. Compounded VIP nasal spray is prescribed off-label by physicians experienced in biotoxin illness treatment.
How long does VIP peptide take to work?
In CIRS treatment, biomarker improvements (TGF-beta1, MMP-9, C4a) typically begin within 2 to 4 weeks. Symptom improvements including reduced fatigue, better cognitive function, and improved breathing often follow within 4 to 8 weeks. Full protocol completion usually takes 30 to 90 days.
What are the side effects of VIP peptide?
At the standard nasal spray dose of 50 mcg four times daily, VIP is well-tolerated with minimal side effects. Possible effects include mild nasal irritation, transient nasal congestion, and occasional mild headache. At higher systemic doses, transient hypotension, facial flushing, and watery diarrhea can occur.
Can VIP peptide be combined with BPC-157 or KPV?
Yes. VIP, BPC-157, and KPV work through different anti-inflammatory mechanisms and can complement each other. VIP modulates systemic immune regulation, BPC-157 drives tissue repair, and KPV suppresses localized NF-kB inflammation. Your physician can design a protocol combining these based on your condition.
How should VIP peptide be stored?
Lyophilized VIP powder should be stored at -20C for long-term stability. Reconstituted nasal spray solutions should be refrigerated at 2-8C and used within 30 days. Protect from light and minimize air exposure to prevent oxidation at the methionine-17 residue. Don't freeze reconstituted solutions.
VIP Peptide Therapy at FormBlends
FormBlends offers physician-supervised VIP peptide therapy for patients dealing with CIRS, chronic inflammation, and related conditions. Our providers have direct experience with the Shoemaker protocol and can guide you through each step, from initial biomarker testing through VIP nasal spray treatment and monitoring.
Unlike platforms that prescribe without thorough evaluation, every FormBlends patient receives a dedicated physician who reviews your full medical history, orders appropriate labs, and designs a treatment protocol specific to your situation. Schedule your consultation to discuss whether VIP therapy is right for you.
References
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217-1218.
- Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacological Reviews. 2004;56(2):249-290.
- Shoemaker RC, House D, Ryan JC. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health. 2013;5(3):396-401.
- Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003;124(4):961-971.
- Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006;107(9):3632-3638.
- Colwell CS, Michel S, Itri J, et al. Disrupted circadian rhythms in VIP- and PHI-deficient mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2003;285(5):R939-R949.
- Petkov V, Mosgoeller W, Giannis A, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation. 2003;111(9):1339-1346.
- Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. Journal of Molecular Medicine. 2002;80(1):16-24.
- Ryan JC, Shoemaker RC. RNA-seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal polypeptide (VIP) shows changes in gene expression. Internal Medicine Review. 2016;2(4).
This content is for informational purposes only and doesn't constitute medical advice. VIP peptide therapy should only be administered under the supervision of a qualified physician. Individual results vary.
Ready when you are
VIP (Vasoactive Intestinal Peptide)
Neuropeptide that regulates inflammation, circadian rhythm, and mucosal immunity · From $59/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about VIP (Vasoactive Intestinal Peptide) →